RiboPro (a spin-off from Mecurna), and Pleco Therapeutics pitched and won a place in the semi-finals at the Global Investor Forum 2021
Citryll announced it has appointed Patrick Round as Chief Medical Officer. Patrick will provide leadership and direction to Clinical development strategy, Clinical Operations, Clinical Affairs, Clinical Sciences, Data
Management/ Biometrics, and Drug Safety.
Onlangs noemde Hans Schikan in FD het een van de bottlenecks van de Nederlandse vaccinstrategie; de vulcapaciteit. De oplossing, die is te vinden in Brabant bij BioConnection B.V. op Pivot Park.
Under the terms of the agreement, Pieris will provide Glycostem with Anticalin constructs against immune targets to be combined with Glycostem’s oNKord® technology to study the combined potential of the technologies in the treatment of solid tumors.
Innovation within the pharmaceutical sector. This topic was discussed more than ever in 2020-2021.
In a paper recently published in the SLAS Discovery Journal of Biomolecular Screening, European Lead Factory (ELF) scientists from Pivot
Over the last few months, as the world has grappled with the COVID-19 pandemic, the European Lead Factory has been
One of the sub-projects of the MMV-PDP Consortium recently received funding from the Bill and Melinda Gates Foundation, to further develop an
Arginase-1 is a promising new drug target for cancer immunotherapy. A novel assay technology for High-Throughput Screening (HTS) of Arginase-1
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.